Research


  • The increase in the survival of patients with advanced cancer and other chronic diseases, modifying the indicators on a population scale in Cuba.

  • The growth of the portfolio of exportable products and conquest of the foreign market based on a differentiation strategy based on scientific knowledge.

  • Scientific discoveries that are translated into new therapeutic concepts and new productive technologies that sustain the sustainable growth of the impact on health and the country's economy.


Reactivos de laboratorio para uso in vitro

categoriaProducto: Commercials

modalidad: Laboratory Reagents

producidoPor: LABEX

ior® Hemo-CIM SC Anti A, Anti B, Anti AB and Anti D For the determination of blood groups of the ABO system, formulated from murine Monoclonal Antibodies (mAbs). Presentation: 5 mL glass dropper bottles for 100 determinations.

Anti-human IgG-FITC To quantify human IgG levels, in serum samples, as part of the evaluation of the humoral immune response. It is useful for the diagnosis and monitoring of therapies in immunohematological, neoplastic and immunological etiology pathologies. Presentation: 1 mL bottles for 10 determinations, containing IgG fraction of sheep serum immunized with human IgG and 0.1% sodium azide as a preservative.

Immunostaining system (IFI) FITC conjugated anti-mouse sheep immunoglobulins. Presentation: 1 mL bottles for 600 determinations, containing immunoglobulins in phosphate buffer solution, 1% bovine albumin serum, 0.1% sodium azide as a preservative agent.

ior® anti-CD3; ior® anti-CD4; ior® anti-CD8 and ior® anti-CD45- FITC It is used for the evaluation of T lymphocytes and in the classification of leukemias and lymphomas. Also for monitoring patients with HIV / AIDS. Presentation:
5 ml flasks, amber, screw cap and a minimum content per vial of 1.1 ml, for 100 determinations.

Hemolysin (CH50) To evaluate the hemolytic activity of the classical pathway of the complement system, so it is useful in many diseases: immunodeficiencies, chronic infections, immunocomplex diseases and other pathologies in which complement is consumed. Presentation: 1 mL bottles for 21 determinations, containing rabbit serum anti ram with erythrocyte stroma and 0.01% thiomersal as a preservative.

Coombs® Serum Coombs serum is a poly-specific human immunoglobulin used in the immuno diagnosis of patients with autoimmune hemolytic anemias and other autoimmune diseases. In addition, it is used for the detection of maternal-fetal Rh conflicts, in the determination of Blood Group Antigens (Rh test) and in pretransfusion tests for the identification of antierithrocytic antibodies in human serum and in sensitized red blood cells in vivo. Presentation: 5 mL flasks for 50 determinations, containing polyspecific anti-human serum, 1% albumin, 0.1% sodium azide as a preservative and 0.0005% erioglaucine and 0.0005% acriflavine as dyes.

nombreComercial: ior® Hemo-CIM SC Anti A, Anti B, Anti AB y Anti D

formaFarmaceutica: no content

propiedadesFarmacologicas: no content

indicacionesTerapeuticas: no content

aprobacionesEspecialesComercializacion: no content

Phone Board:
53-7-2717933
General Direction:
53-7-2714335
15 Street and 216 Street, Siboney, Playa, La Habana, Cuba. A.P 16040, La Habana 11600, Cuba
Postal Code:
11 600
Post Office Box:
16 040

Spot

Video

Bulletin CIM

¡Stay informed of our latest news!

Cancel subscription

Frequent Questions

How can I access the therapeutic vaccine against lung cancer CIMAvax-EGF?


CIMAvax EGF ® is a therapeutic vaccine registered in Cuba (developed by the Center of Molecular Immunology (CIM), for advanced lung cancer. This therapeutic vaccine has a health history in the indication: Advanced non-small cell lung cancer (NSCLC) stage IIIb and IV, after the first line of chemotherapy. It is in this condition and type of lung cancer that the greatest clinical benefit is obtained in terms of increased survival and improved quality of life, as well as a broad safety profile in treated patients. This vaccine is not recommended for other types of cancer, apart from NSCLC, the tumor must be primary pulmonary, because we have no evidence of efficacy to date. It is necessary to know the histology and tumor stage of the patient, since CIMAvax EGF ® is only registered for non-small cell lung cancer of advanced stage IIIb and IV cells (NSCLC), in other types of tumors we have no evidence of clinical efficacy .

Questions of Interest:
Position of CIM for CIMAvax EGF®:

The Center for Molecular Immunology (CIM) is the center where it develops, produces and markets this medicine among other biotechnological products. This institution does not offer treatments to patients directly, nor does it inform about the price of the products they produce.

Foreign patients should contact the Cuban Medical Services who will evaluate each case if they are susceptible to treatment with these vaccines and receive it within a comprehensive program of patient care with commercial value.
You can contact them at these addresses:

Cuban Medical Services.
Web Page: www.smcsalud.cu; E-mail: smc@smcsalud.cu
Phones: (537) 209-0977
Fax: (537) 203-1590

At the International Clinic La Pradera:
Phones (537) 2737467 ext. 403
Commercial: 72731441
Relacinternac@cislapradera.cu

If you want a treatment outside of Cuba:

Paraguay
Laboratorio Libra Paraguay S.A
Dirección: Pedro Ciancio 1443 entre Santiago y San Cosme B Jara Asunción Persona de Contacto: Sr. Pablo Moreira Gerente Comercial
Correo electrónico: pmoreira@lablibra.com
Teléfono: (595-21) 228 370
Móvil: (595) 986 679300

Colombia
LABORATORIOS DELTA
Sr. Alejandro Castaño.
Gerente general
Alejandrodelta@deltamedecine.com
Tel: + 57-4-334 40 33
Móvil: +57 - 311 301 8257
Skype: Alejandrodelta
Www.deltamedicine.com
Cra.46 # 19 sur 117
Medellín, Colombia, América del Sur

Argentina
Laboratorio Elea Phoenix S.A.
Sanabria 2353 (C1417AZE), Ciudad Autónoma de Buenos Aires, Argentina
Tel. (5411) 4379 4300 (int. 1266)
www.elea.com
Director médico Dr. Matias DEPRATI
Email: DEPRATIM@elea.com

Kazajistán
LLP UM-Pharma
УМ-Фарм
050033, Almaty, Khodzhanova street, 13 house, 69
CEO. Alina Ilimbayeva
+7 701 715 6000

Bosnia Herzegovina
VAMA d.o.o.
Kraljice Natalije 46
11.000 Beograd
Tel: +381 11 36 28 433
www.vama.rs
CEO. Mr. Zoran Vujovic.

Si necesita cualquier información adicional, no dude en contactarnos.
Saludos cordiales.

Mas preguntas frecuentes...

Poll

Welcome to the CIM survey, we value your opinion and thank you for dedicating your time

We would love to know how you like our site
Excellent
40% (7660 votes)
Very Good
38% (7242 votes)
Good
6% (1283 votes)
Regular
14% (2692 votes)
Bad
0% (2 votes)


Site Map Terms and Conditions Privacy Policy